Sionna Therapeutics and Vectus Biosystems target orphan lung disease markets

Sionna Therapeutics, a clinical‑stage biotech valued at about $2.2 billion, is developing a therapy that could restore normal CFTR protein function in cystic fibrosis. If successful, the drug could challenge Vertex Pharmaceuticals, which generates roughly $3.2 billion in cystic fibrosis sales and dominates the market with a valuation near $123 billion.

Australian ASX‑listed Vectus Biosystems has shifted its focus to the orphan indication idiopathic pulmonary fibrosis (IPF). Under CEO Dr Tara Speranza, the company is advancing oral vasoactive intestinal peptide (VIP) molecules that aim to reverse lung fibrosis, positioning itself against three existing IPF treatments.

Both companies illustrate a broader trend of biotech firms pursuing niche, high‑need lung‑disease markets, seeking to capture sizable revenue opportunities despite the challenges of rare‑disease development.